Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Blank, C.U.
  • (-) ≠ Scholarly Publications
  • (-) = Suijkerbuijk, K.P.M.

Refine Results

Resource Type

Availability

Creation Date

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 26)

Pages

Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nationwide cohort of advanced melanoma patients in the Netherlands
Adjuvant BRAF-MEK inhibitors versus Anti PD-1 Therapy in stage III melanoma
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
ASO visual abstract
Association of immune-related adverse event management with survival in patients with advanced melanoma
Is a history of optimal staging by sentinel lymph node biopsy in the era prior to adjuvant therapy associated with improved outcome once melanoma Patients have progressed to advanced disease?
End-of-life use of systemic therapy in patients with advanced melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma
Response to immune checkpoint inhibitors in acral melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
The unfavorable effects of COVID-19 on Dutch advanced melanoma care
Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients
Survival of stage IV melanoma in Belgium and the Netherlands
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition
Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors
Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease
Nationwide outcomes of advanced melanoma according to BRAF(V600) status
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients

Pages